NCT02007044View on ClinicalTrials.gov

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 6, 2013

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER